Pathogenics licenses rights to anti-infective compound for ophthalmological use

By Lisa Kerner

Erie, Pa., April 19 - Pathogenics, Inc. said it has licensed to Acuity Pharmaceuticals, Inc. the exclusive worldwide rights to N-Chlorotaurine, a novel anti-infective compound for the treatment of ophthalmic infections and other diseases such as viral conjunctivitis, bacterial conjunctivitis and herpetic keratitis.

Acuity is paying Pathogenics an up-front licensing fee, minimum annual license fees, development milestones and royalties. In addition, Acuity is responsible for clinical development, regulatory activities and commercialization of the compound in ophthalmic indications.

Pathogenics retains the exclusive worldwide rights to N-Chlorotaurine for all indications other than ophthalmic applications.

Further details of the agreement were not disclosed.

Pathogenics is a biopharmaceutical company located in Hingham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.